A Study of AT-02 in Systemic Amyloidosis
This study is testing AT-02, an investigational medicine, for people with systemic amyloidosis. Systemic amyloidosis is a condition where abnormal proteins build up in organs. The main goals are to understand the safety and how well AT-02 is tolerated over a long period, up to 112 weeks. Researchers will look at any side effects and changes in your lab results. You may be able to join if you are 18 to 85 years old, have a confirmed diagnosis of AL amyloidosis, and meet other specific criteria. This study is for people who previously participated in the AT02-001 study, or for those with AL amyloidosis and kidney disease who did not.
- Study design
- This is an open-label extension study, meaning both you and your doctors will know you are receiving AT-02. It plans to enroll 120 participants.
- What's involved
- You would participate in the study for up to 120 weeks, which includes a screening period, a treatment period lasting up to 104 weeks, and a follow-up period.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and lab results will be monitored for up to 112 weeks after starting the study.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of AT-02 in Subjects With Systemic Amyloidosis.
At a glance
Conditions
Where it's being run
4 sites across 4 statesWho to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Incidence, frequency, and severity of Treatment-emergent adverse events (TEAEs) as assessed National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0)Up to 112 weeks
- To assess the safety and tolerability of AT-02 through change from baseline in clinical laboratory resultsUp to 112 weeks